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Sickle cell disease 
a b s t r a c t 
Background: There is limited information on the safety or eﬃcacy of currently recommended antimalarial 
drugs in patients with sickle cell disease (SCD), a population predisposed to worse outcomes if affected 
by acute malaria. Artesunate-amodiaquine (ASAQ) is the ﬁrst-line treatment for uncomplicated malaria 
(UM) in many malaria-endemic countries and is also used for treatment of UM in SCD patients. There 
is, however, no information to date, on the pharmacokinetics (PK) of amodiaquine or artesunate or the 
metabolites of these drugs in SCD patients. 
Objectives: This study sought to determine the PK of desethylamodiaquine (DEAQ), the main active 
metabolite of amodiaquine, among paediatric SCD patients with UM treated with artesunate-amodiaquine 
(ASAQ). 
Methods: Plasma concentration-time data (median DEAQ levels) of SCD children (n = 16) was initially 
compared with those of concurrently recruited non-SCD paediatric patients with acute UM (n = 13). A 
population PK modelling approach was then used to analyze plasma DEAQ concentrations obtained be- 
tween 64 and 169 hours after oral administration of ASAQ in paediatric SCD patients with acute UM 
(n = 16). To improve PK modeling, DEAQ concentration-time data (n = 21) from SCD was merged with 
DEAQ concentration-time data (n = 169) of a historical paediatric population treated with ASAQ (n = 103) 
from the same study setting. 
Results: The median DEAQ concentrations on days 3 and 7 were comparatively lower in the SCD pa- 
tients compared to the non-SCD patients. A two-compartment model best described the plasma DEAQ 
concentration-time data of the merged data (current SCD data and historical data). The estimated popu- 
lation clearance of DEAQ was higher in the SCD patients (67 L/h, 21% relative standard error (RSE) com- 
pared with the non-SCD population (15.5 L/h, 32% RSE). The central volume of distribution was larger in 
the SCD patients compared with the non-SCD patients (4400 L, 43% RSE vs. 368 L, 34% RSE). 
Conclusions: The data shows a tendency towards lower DEAQ concentration in SCD patients and the ex- 
ploratory population PK estimates suggest altered DEAQ disposition in SCD patients with acute UM. These 
ﬁndings, which if conﬁrmed, may reﬂect pathophysiological changes associated with SCD on DEAQ dispo- 
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i  ntroduction 
Sickle cell disease (SCD) is a common autosomal recessive ge-
etic disorder caused by a single nucleotide substitution (T > A)
n the sixth codon of the β-globin gene. The single point muta-
ion resulting in a Glu to Val substitution promotes polymerization
nd precipitation of haemoglobin S (HbS) during deoxygenation or
ehydration, resulting in sickling of red blood cells. The associ-
ted pathophysiological changes result in vaso-occlusive crises and
ther clinical manifestations of SCD, and ultimately, organ dam-
ge. 1 The highest frequencies of homozygous SCD are found in sub-
aharan Africa, and although a linkage exists between the presence
f sickle haemoglobin (HbS) and protection from malaria in the
eterozygous state, 2,3 malaria is a frequent cause of hospitalization
nd poor outcome among children with homozygous SCD in en-
emic areas 4,5 and malaria is associated with a higher mortality in
ospitalized SCD patients. 6–8 These imply the need to ensure ef-
cacious antimalarial therapy in SCD patients who develop acute
alaria but information on the eﬃcacy or safety of recommended
ntimalarial drugs in SCD patients is limited or non-existent. 
Amodiaquine (AQ) is currently used in combination with
rtesunate (AS) as ﬁrst-line treatment for uncomplicated falci-
arum malaria (UM) in many countries. AQ is a 4-aminoquinoline
etabolized by hepatic cytochrome P450 2C8 (CYP2C8) to desethy-
amodiaquine (DEAQ) its active metabolite, which is subsequently
liminated via extra-hepatic biotransformation by CYP1A1 and
YP1B1. 9 DEAQ is primarily responsible for the pharmacological
ctivity of AQ (parent drug), due to its long elimination half-life. 10 
he pharmacokinetics (PK) of AQ when used in combination with
rtesunate (AS), has been described in healthy volunteers, 11,12 chil-
ren, 13–15 and adults, 16 with UM. Estimates of DEAQ clearance have
een reported to range between 6–17 L/h, 13,14 and distribution
olume between 350–500 L, 13,14 in non-SCD children. There is the
ossibility that the disposition of AQ could be altered in patients
ith SCD given anticipated pathophysiological changes in SCD
atients. It is known that both white blood cells and platelets accu-
ulate large amounts of chloroquine, 17 therefore, excessive throm-
ocytosis or leukocytosis, both of which are features of SCD, could
lter the distribution of this 4-aminoquinoline in blood. Indeed,
lasma concentrations of chloroquine and desethylchloroquine,
ts major metabolite have been shown to differ between SCD and
on-SCD erythrocytes in vivo and in vitro. 18 There are no reports
n the PK of AQ or DEAQ in SCD patients. In this study, the PK of
EAQ in paediatric SCD patients with acute UM who participated
n a clinical trial and received treatment with ASAQ is described. 
ethods 
tudy site 
The study was a sub-component of a clinical trial (IS-
CTN96891086) that was conducted to evaluate the eﬃcacy and
afety of ASAQ and artemether-lumefantrine (AR-L) among SCD
nd non-SCD children with acute UM. The study was conducted at
he Outpatients Department (OPD) and Paediatric Sickle Cell Clinic
f the Department of Child Health, Korle Bu Teaching Hospital,rapeutic response to amodiaquine in SCD patients. The limited number of
rse sampling approach however, limits extrapolation of the data, and calls
opulation. 
© 2019 Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license.
( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
ccra, Ghana, between January 2010 and December 2011. The full
etails of the clinical trial have been previously reported. 19 Brieﬂy,
hildren of known SCD status registered at the Paediatric Sickle
ell Clinic who presented to the Paediatric Emergency Department
r the Paediatric Sickle Cell Clinic with an acute febrile illness
onﬁrmed parasitologically to be UM were recruited, if they ful-
lled study criteria and if written informed consent was obtained
rom an accompanying parent or guardian. Recruited children
ere treated with ASAQ or AR-L and followed up on days 1, 2, 3,
, 14, 28, 35, and 42, according to a pre-deﬁned schedule. Ethical
pproval was obtained from the Ethical and Protocol Review Com-
ittee, University of Ghana Medical School. Inclusion criteria for
he study were, child of conﬁrmed SCD status aged six months to
2 years with an acute febrile illness (history of fever within
he previous 72 hours, or an axillary temperature ≥37.5 °C at
resentation; Plasmodium falciparum infection of parasite den-
ity < 20 0,0 0 0/μL; and, willingness of the accompanying par-
nt/guardian to comply with the study procedures and follow-up
chedule). Exclusion criteria were, symptoms or signs of severe
alaria; known intolerance or allergy to study medications;
nd, reported treatment with any of the study drugs one-month
receding enrolment. 
rug dosing 
ASAQ (Coarsucam; Sanoﬁ Aventis, France; 25/50/100 mg arte-
unate and 67.5/135/270 mg amodiaquine) single daily dose,
as administered for three days according to body weight:
4.5 - < 9 kg (25 mg/67.7 mg), one tablet/dose; ≥9 - < 18 kg
50 mg/135 mg), one tablet/dose; ≥18 - < 36 kg (100 mg/270 mg),
ne tablet/dose; ≥36 kg (100 mg/270 mg) two tablets/dose. 
lood sampling 
A venous blood sample (2–5 ml) was collected into heparinized
olypropylene tubes before treatment and on days 3 or 7 in chil-
ren who were haemodynamically stable and/or in whom a blood
ample was required for laboratory analysis for clinical manage-
ent. The heparinized blood was immediately centrifuged, and
lasma was transferred into polypropylene tubes and stored at
20 °C until analysis. The exact time of drug administration was
ecorded for each participant on days 0, 1, and 2, and the exact
ime of blood sampling was recorded on days 3 or 7. 
igh Performance Liquid Chromatographic (HPLC) 
The concentrations of DEAQ were measured in plasma by
eans of a reverse-phase HPLC method. Heparinized plasma
amples (100 μl) were pipetted into 10 ml glass tubes and 90 μl
illi-Q water, 200 μl sodium carbonate buffer (0.2 M, pH 9.5) and
0 0 0 μl tert-butylmethylether were added. After reciprocal shaking
or 20 min. and centrifugation (30 0 0 rpm., 10 min.) the organic
hase was transferred to new tubes and extracted for 20 min. with
20 μl of phosphate buffer (0.1 M, pH 4). After separation, the or-
anic phase was discarded, and the aqueous phase was transferred
nto polypropylene HPLC vials. Aliquots of 90 μl were injected into


































































Baseline demographic characteristics and plasma levels of desethylamodiaquine 
(DEAQ) on days 3 and 7 after administration of ﬁrst amodiaquine dose among re- 
cruited children with sickle cell disease (SCD) and without SCD. 
Parameter SCD (n = 16) No SCD (n = 13) P value 
n (%) 
Male sex 6 (37.5) 7 (53.8) 
median (range) 
Age (y) 9 (1.9–13.8) 6 (2–11) 0.15 
Parasite density (/μL) 652 (48–63,360) 24240 (160–148,160) 0.001 
Haemoglobin (g/dL) 6.3 (3.6–12.8) 10 (5.8–12.2) 0.004 
White blood cells (10 9 /L) 12.8 (6–73.4) 9.3 (6.1–19.3) 0.14 
Platelet count (10 9 /L) 201 (87–813) 152 (41–283) 0.03 
Day 3 DEAQ (ng/mL) 72.0 (20–169.3) 117.6 (36–317) 0.27 








































S  he chromatograph. The HPLC system consisted of an 1100 Quater-
ary pump with 1100 Degasser and an 1100 Autosampler (Agilent
echnologies (Palo Alto, CA, USA) with a Zorbax SB-CN column,
μm (4.6 ×250 mm) (Agilent), protected by a LiChroCART ® 4-4
iChrospher ® 100 RP-18 (5 μm) guard column (Merck, Darmstadt,
ermany). The mobile phase was acetonitrile-phosphate buffer 
0.1 M, pH 2.3)-sodium perchlorate (1 M) (14:85:1) operating at
 ﬂow rate of 1.2 ml/min. The wavelength was set at 237 nm
1100 Diode array detector, Agilent Technologies). The within-day,
ntra-assay variation was determined by replicate analysis of
amples spiked with different concentrations. The between-day,
nter-assay variation was performed by two determinations at
ach concentration on different days. Five calibrators were run in
uplicate each day of analysis. Accuracy was determined by repli-
ate analysis of spiked plasma samples. The recovery in plasma
t three different concentrations were determined by comparing
eak areas obtained after extraction of spiked human plasma with
hose of directly injected standards dissolved in the mobile phase.
he limit of quantitation (100 μl) was 10 ng/ml, and coeﬃcient of
ariation (CV) was < 10%. 
K model building 
The total AQ dose, number of administered (AQ) doses,
ampling and dosing times, plasma DEAQ concentrations, and
emographic information was available. The sampling time was
alculated relative to the time of ﬁrst drug administration, and
rug concentrations below LOQ (3 time points) were excluded. 
A nonlinear mixed-effects modeling approach was applied
o estimate the PK parameters of DEAQ, using NONMEM
Version 7.3, ICON Development Solutions, Ireland), with Pirana ®
oftware (Version 2.8.2, Pirana Software and Consulting BV) and
he First Order Conditional Estimation with Interaction (FOCEI)
lgorithm for the model building. Graphical analysis of model out-
uts and covariate analysis were explored, using R Software ® (Ver-
ion 3.0.2), and R Package Xpose ® (Uppsala University, Sweden). 
Due to a high eta-shrinkage and poor goodness of ﬁt plots (due
o the sparse data and limited sample size) from the 16 sickle
ell disease (SCD) children (21 concentration-time points), and 13
on-sickle cell patients (14 concentrations-time points), the data
rom the SCD patients was merged with a previous dataset that
escribed the PK of DEAQ in 103 non-SCD children (169 mea-
urable DEAQ concentration-time points) with UM in the same
tudy setting, 13 giving a total of 190 concentration time points.
f these 103 children, 15 (median age = 5.3 years; median body
eight = 18 kg) received AQ only, whilst 88 (median age = 6.0
ears; median body weight = 18 kg) received AS plus AQ. After
erging the data, SCD was included in the model as categorical
ovariate. 
For the structural PK model, one- and two-compartmental
odels with ﬁrst order absorption were ﬁtted to the plasma DEAQ
oncentration-time data. The two-compartment model appeared 
o describe data better, based on the objective function. Due to
he lack of data on the absorptive phase of AQ disposition, the
bsorption rate constant (K a ) and lag time (T lag ) were ﬁxed at
.867 h −1 and 0.84 h, respectively, as described previously. 13 
urthermore, the ﬁxed Ka was viewed as a hybrid parameter that
ncludes the Ka of AQ, the volume of distribution (V 1 ) of AQ, and
he formation clearance (CL1/ f ) of DEAQ, as described previously. 13 
herefore, the two-compartment model was parametrized as clear-
nce (CL/ f ), central volume of distribution (V2/ f ), intercompartmen-
al clearance (Q/ f ), and peripheral volume of distribution (V3/ f ).
etween patient variability (BPV) was modeled exponentially 
ssuming a log normal distribution. BPV was estimated assuming
arameters had a mean of zero, and a variance of omega squared
 ω 2 ). Additive, proportional and combined error models wereested in the model building process, and residual error was as-
umed to have a mean of zero and variance of sigma squared ( σ 2 ).
he effect of age, body weight and sex were explored as covariates
n the PK parameters. These covariates were retained in the model
f they improved ﬁt (backward elimination and forward inclusion).
llometric scaling of all distribution parameters were done as re-
orted by Holford. 20 Models were compared by the likelihood ratio
est, represented in NONMEM as a difference in objective function
alue ( OFV) of 3.84, and corresponding to a level of signiﬁcance
f < 0.05, and by using a decrease in the variance of random
ffects, eta-shrinkage and goodness of ﬁt plots [observed (DV) vs.
ndividual-predicted (IPRED) and population predicted (PRED), as 
ell as conditional weighted residuals (CWRES) vs. PRED]. 
The model that best described the data was evaluated by means
f visual predictive check (VPC). 
tatistical analysis 
Entire pharmacokinetic modeling process (software used, 
escription of structural and statistical models, model com-
arison and evaluation) have been described earlier. Continuous
ariables were summarized as medians with accompanying ranges,
nd group medians compared with Wilcoxon signed-rank test.
 p value < 0.05 was considered statistically signiﬁcant. 
esults 
haracteristics of patients and plasma DEAQ concentrations on days 
 and 7 
All recruited participants demonstrated an adequate clinical and
arasitological response. The median age of the SCD patients was
igher, and admission parasitaemia was lower, compared to the
on-SCD group. There was a total of 35 measurable plasma DEAQ
oncentrations above LOQ from 16 SCD (n = 21), and 13 non-SCD
n = 14) patients obtained between 64.3 and 169.2 hours. There
ere comparatively lower (though statistically non-signiﬁcant) 
EAQ concentrations amongst the SCD children compared to the
on-SCD children on Days 3 (p = 0.27) and 7 (p = 0.12). The base-
ine demographic characteristics and median DEAQ concentrations 
f SCD and non-SCD children on day 3 (SCD, n = 10: non-SCD,
 = 8) and day 7 (SCD, n = 11: non-SCD, n = 6) is shown ( Table 1 ). 
opulation PK modelling of DEAQ plasma concentrations of merged 
ata [SCD (n = 16) and non-SCD (n = 103) children] 
The DEAQ plasma concentration from the merged data of
CD children (21 concentration-time points) and non-SCD (169
12 G.O. Adjei, S.K. Amponsah and B.Q. Goka et al. / Current Therapeutic Research 90 (2019) 9–15 
Figure 1. Clearance derived from the base model of merged data versus body 













































































S  oncentration-time points) showed that a two-compartment best
escribed the base model. The PK parameter versus covariate
lot of the merged data showed that body weight would explain
ome of the variability in DEAQ clearance, as shown in Figure 1 .
arametrization of the two-compartment model and application of
llometric scaling yielded a much better ﬁt, and diagnostic plots of
he best model that described data are shown ( Figures 2 A and B).
his model had a variance in BPV of 32.6% on CL (26% shrinkage)
nd 49.6% on V 2 (67% shrinkage). A set of simulated datasets
enerated, using the best model was compared to real observa-
ions, i.e., VPC, which showed that the sparse (plasma DEAQ)
bservations limited the creation of an appropriately ro-
ust model for the current dataset. The VPC of the historical
ataset ( Figure 3 A), and the DEAQ data of the children with SCD
 Figure 3 B), are shown. 
The parameter covariate plots of CL and central volume of
istribution (V 2 ) of DEAQ among non-SCD and SCD children of the
erged dataset, with inclusion of SCD as a categorical covariate
n the model, are shown ( Figures 4 A and B), respectively. The
opulation clearance and volume of distribution of DEAQ in SCD
nd non-SCD children is summarized in Table 2 . Population CL
as found to be approximately 5-fold greater in the SCD children
ompared to the non-SCD children. The population V 2 of DEAQ for
he children with SCD children was more than 10-fold that of theon-SCD children. 
Table 2 
Estimated population pharmacokinetic parameters of desethylamodiaquine in pat
cell disease (n = 103). 
Sickle cell disease (n = 16) N
Parameter Unit Estimate Relative SE (%) P
Absorption rate constant h −1 0.867 (ﬁxed) A
Lag time h 0.84 (ﬁxed) L
Clearance L/h 67 21 C
Central volume of distribution L 4400 43 Ciscussion 
In this study, we used a population PK modelling approach
o estimate selected primary PK parameters of DEAQ in a limited
ample of SCD children versus non-SCD children treated with ASAQ
or acute uncomplicated falciparum malaria. We are not aware of
ny previous report on the PK of antimalarial drugs in SCD pa-
ients with acute malaria. The data is consistent with previous
tudies that have showed wide inter-individual variation in DEAQ
oncentrations. 21 The relatively low day 3 and day 7 plasma DEAQ
oncentrations in the SCD patients are comparable to similarly low
lasma DEAQ concentrations demonstrated in HIV-infected chil-
ren treated with ASAQ, 22 but almost two-fold lower on average,
han plasma DEAQ concentrations of non-SCD children. 13–15 , 23 
The low day 3 DEAQ concentrations in the SCD patients
ould be due to excessive thrombosis and leukocytosis in SCD
atients, 19 and to associated pathophysiological changes in SCD
ncluding hyposthenuria and hyperﬁltration, 24,25 which could be
cting in concert with increased hepatic and renal blood ﬂow
rom increased cardiac output or chronic haemolytic anaemia,
o accelerate solute (drug) clearance. 26–28 Impaired hepatic and
enal blood ﬂow has been linked to elevated morphine clearance
n SCD patients, 29 and to impaired lidocaine metabolism. 30 The
arge differences in clearance and volume of distribution is also
onsistent with the results of several studies that have shown dif-
erences in PK parameters between SCD and non-SCD populations
or various drugs: the clearance of ciproﬂoxacin is reported to be
9% higher in SCD patients compared to non-SCD patients; 31 ce-
otaxime clearance has been shown to be higher in SCD patients,
nd higher still in SCD patients with acute chest syndrome; 32 
nd morphine clearance is reported to be 3-10 fold higher in
CD patients compared to published estimates in the non-SCD
opulation. 29 The chronic inﬂammation in SCD may also induce
rug metabolism, as demonstrated for codeine in SCD patients. 33 
t is also plausible that other commonly occurring changes in
CD patients including malnutrition, 34,35 a condition reported in
p to 63% of SCD children in our study setting, 36 and which is
ssociated among others, with increase in total body water and
ypoalbuminaemia, increases the unbound drug concentration
nd thus, alter the kinetics of drug disposition. However, due to
he physicochemical characteristics of amodiaquine, the overall
harmacodynamic effect(s) of these PK parameter changes in
CD patients, on the therapeutic effect of amodiaquine, given the
nterplay of multiple factors, is diﬃcult to anticipate. 
The limitation of the study is the limited sample and sparse
ataset and resulting high shrinkage on the PK parameter esti-
ates. These places limitations on the robustness of the model and
n interpretation or extrapolation of the ﬁndings. These limitations
otwithstanding, we consider the data and ﬁndings to be poten-
ially important because there is lack of data on the pharmacoki-
etics of amodiaquine, a widely used antimalarial drug, in SCD and
on-SCD patients. Given the higher malaria-associated mortality in
CD, diﬃculty in recruiting suﬃcient number of parasitologically-ients with pediatric sickle cell disease (n = 16) and without pediatric sickle 
o sickle cell disease (n = 103) 
arameter Unit Estimate Relative SE (%) 
bsorption rate constant h −1 0.867 (ﬁxed) 
ag time h 0.84 (ﬁxed) 
learance L/h 15.5 32 
entral volume of distribution L 368 34 
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Figure 2. A: Merged observed dataset versus population and individual predictions from the most appropriate model. Red line shows how best the ﬁnal model is able to predict 















conﬁrmed malaria patients among SCD patients, the diﬃculties
f taking multiple blood samples from such a chronic haemolytic
naemia prone paediatric SCD patients and the ethical implications
f multiple blood sampling in such a vulnerable population, the
ndings from this limited dataset, obtained during routine clinical
rocedures, provides important preliminary information in a pop-
lation in which such information is lacking and in which such a
ataset is diﬃcult to obtain. In summary, we have employed a population modelling ap-
roach (merging sparse SCD data with historical data) to estimate
rimary PK parameters of DEAQ in paediatric SCD patients, a pop-
lation in which such data is lacking. The ﬁndings suggest altered
EAQ disposition in SCD patients which calls for further stud-
es and raise questions on potential therapeutic effects of these
hanges on amodiaquine use in SCD patients. 
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Figure 3. A: Visual Predictive Check (VPC) of DEAQ observations (ng/ml) versus time (h) of non-SCD (n = 103). B: Visual Predictive Check (VPC) of DEAQ observations (ng/ml) 
versus time (h) of SCD (n = 16). Blue half circles are individual observations, solid and doted red lines – observation percentile intervals (upper 5%, lower 5% and a median), 
the blue and orange areas are 95% conﬁdence intervals around each of the prediction percentile intervals obtained by simulation. 
Figure 4. A: Population Clearance (L/h) of DEAQ derived from the most appropriate model after merged data among SCD and non-SCD children. B: Population V 2 (L) of 
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